Advertisement
 
YOU ARE HERE: LAT HomeCollectionsBiomedical Research
IN THE NEWS

Biomedical Research

CALIFORNIA | LOCAL
May 15, 2010 | By Joseph Serna, Los Angeles Times
The first-of-its kind stem cell research facility opened Friday at UC Irvine, with leading scientists and state officials on hand to do the honors. UC Irvine's Sue and Bill Gross Hall: A California Institute for Regenerative Medicine is the first of seven such facilities the state agency plans to open for stem cell research at California universities. The statewide regenerative medicine agency was created after passage of Proposition 71 in 2004 by 59% of voters, who supported new funding sources for stem cell research after then-President George W. Bush banned federal funding to develop new stem cell lines.
Advertisement
OPINION
March 18, 2009
Re "Clinical research lacks for patients," March 14 The Times' article misses a key point: There are too many clinical trials. As a biomedical research administrator, I know that many incentives for clinical trials are institutional, not scientific. Organizations are often evaluated on the number of trials they perform, clinical faculty must conduct trials to be promoted, and donors are more likely to contribute if a discovery is tested on patients rather than going through years of (necessary)
CALIFORNIA | LOCAL
February 16, 2005 | Wendy Thermos, Times Staff Writer
Los Angeles city and county officials announced a plan Tuesday to convert a shabby industrial swath near County-USC Medical Center into a gleaming research hub for world-class biomedical advances.
NATIONAL
October 1, 2003 | From Associated Press
Boston University and the University of Texas won a national competition to build high-security laboratories to research deadly viruses as part of the Bush administration's campaign to broaden defenses against bioterrorism. The National Biocontainment Laboratories will house hundreds of scientists researching vaccines and handling deadly agents such as anthrax, bubonic plague and smallpox. Each university will receive a $120-million federal grant for construction.
OPINION
September 4, 2002 | KENNETH P. TREVETT, Kenneth P. Trevett is president and chief executive of the Research and Education Institute at Harbor-UCLA Medical Center.
Each day, tens of thousands of Americans discover their cholesterol levels are high, and their doctors recommend lifestyle and nutrition changes and perhaps medication that reduces the risk of a heart attack or stroke. Each day, thousands of babies are born and are immediately tested to determine whether their thyroid glands are functioning properly; if not, they are given synthetic hormones that prevent devastating and irreversible developmental disabilities.
BUSINESS
May 2, 2002 | Ronald D. White
Pfizer Inc., the nation's largest drug maker, said Wednesday that it will build a major biomedical research campus in La Jolla where more than 1,000 scientists will work on drug discovery. The Pfizer La Jolla site will be built on the current facilities of Agouron Pharmaceuticals, which Pfizer acquired in June 2000. The campus eventually will include eight buildings and 800,000 square feet of space, representing an investment of $155 million, a spokesman said.
OPINION
April 30, 2002 | FRANKLIN HUANG and MATT STREMLAU, Franklin Huang is a medical student at Washington University School of Medicine. Matt Stremlau is a molecular biology PhD candidate at Harvard Medical School.
Of the 300 or so candidates seeking doctorates in molecular biology at Harvard Medical School, only two are studying malaria, a disease that kills at least one African every 30 seconds. Unfortunately, the paltry level of interest expressed by today's young scientists in curing diseases that affect the poorest of the poor is not surprising.
OPINION
April 18, 2002
"Off Track on Cell Research," your April 11 editorial on cloning, raised important issues. As director of the City of Hope Comprehensive Cancer Center, I agree that Sen. Sam Brownback's (R-Kan.) bill that would ban research on therapeutic stem cell cloning would have unfortunate consequences. I disagree with the contention that the bill would drive public research into the private sector. Much more damaging is that the bill would drive research on therapeutic cloning out of the country by making it a criminal offense.
BUSINESS
December 26, 2001
Universities and federal health officials must do more to prevent financial conflicts that could taint biomedical research and harm human subjects, a congressional review says. The study by the General Accounting Office, the investigative arm of Congress, found that researchers do not have to disclose their financial interests to independent review boards, even though the boards must evaluate projects for risks to human subjects.
HEALTH
July 2, 2001 | SUSAN LEVINE, WASHINGTON POST
She noticed the cough almost immediately, began feeling short of breath and achy. Two days after her visit for a research study at the Johns Hopkins Asthma and Allergy Center--two days after inhaling the chemical hexamethonium during what was assumed to be a low-risk test for a healthy young woman--Ellen Roche called back, obviously concerned. Her symptoms were troubling enough that the staff quickly started monitoring her condition.
Los Angeles Times Articles
|